Background

John Murphy, CEO COV-19 Long-haul Foundation

Persistent dermatologic manifestations represent an increasingly recognized component of post-acute sequelae of SARS-CoV-2 infection (PASC), commonly termed Long COVID. Among these manifestations, chronic urticaria, severe pruritus, mast-cell activation syndromes, dysautonomia-associated flushing, livedoid eruptions, chilblain-like lesions, vasculitic syndromes, and persistent inflammatory dermatoses have emerged as clinically significant yet incompletely understood complications. Similar cutaneous syndromes have also been reported following SARS-CoV-2 vaccination, although current evidence suggests these events are uncommon and substantially less frequent than dermatologic complications associated with infection itself. Recent advances in immunology, transcriptomics, single-cell sequencing, proteomics, and vascular biology have provided important insights into the mechanisms underlying persistent dermatologic disease after viral exposure.

Objectives

To critically review current evidence regarding the epidemiology, pathophysiology, genomics, clinical presentation, progression, treatment, and ongoing research concerning chronic urticarial itching and skin abnormalities associated with Long COVID and, less commonly, post-vaccination syndromes.

Findings

Current evidence suggests persistent immune dysregulation, viral persistence, endothelial injury, mast-cell activation, microvascular dysfunction, autoantibody formation, complement activation, and aberrant interferon signaling contribute to chronic dermatologic manifestations. Emerging genomic analyses implicate dysregulated innate immunity pathways, HLA-associated susceptibility loci, mast-cell signaling networks, interferon-response genes, and persistent inflammatory transcriptional signatures. Therapeutic approaches under investigation include antihistamines, mast-cell stabilizers, biologics targeting IgE and IL-4/IL-13 pathways, immunomodulators, antivirals, complement inhibitors, and personalized precision-medicine approaches.

Conclusions

Long COVID-associated dermatologic disease appears to represent a heterogeneous syndrome arising from overlapping immunologic and vascular mechanisms. Future therapeutic success will likely require biologically stratified treatment approaches targeting distinct mechanistic endotypes rather than a single disease entity.

Introduction

Five years after the emergence of SARS-CoV-2, Long COVID remains one of the most significant chronic disease burdens resulting from the pandemic. Although neurologic, cardiopulmonary, and autonomic manifestations have received substantial attention, persistent dermatologic complications are increasingly recognized as major contributors to morbidity and diminished quality of life. Urticarial eruptions, severe pruritus, dysesthetic skin sensations, vasculopathic lesions, inflammatory dermatoses, and chronic mast-cell activation phenotypes may persist months or years following acute infection.

Dermatologic manifestations are uniquely positioned at the intersection of immune dysfunction and vascular pathology. The skin functions as both an immunologic organ and a microvascular network, making it particularly vulnerable to the persistent inflammatory disturbances characteristic of Long COVID.

Recent investigations have revealed that many cutaneous symptoms previously considered isolated dermatologic phenomena may instead represent visible manifestations of systemic immunologic dysfunction involving mast cells, endothelial cells, complement pathways, coagulation systems, and autonomic regulation.

Epidemiology

The true prevalence of Long COVID-associated dermatologic disease remains uncertain because definitions vary substantially among studies.

Large cohort analyses suggest approximately 10–20% of Long COVID patients report persistent dermatologic symptoms, although prevalence varies according to population studied and duration of follow-up. Common manifestations include:

Chronic urticaria
Generalized pruritus
Morbilliform eruptions
Livedoid lesions
Chilblain-like lesions
Eczematous dermatitis
Hair loss
Nail abnormalities
Dysautonomia-associated flushing
Vasculitic eruptions

Persistent urticarial disease appears among the most commonly reported dermatologic manifestations. Multiple studies describe onset during acute infection followed by progression into chronic spontaneous urticaria lasting beyond six months.

Post-vaccination chronic urticaria has also been documented. Current evidence indicates that chronic spontaneous urticaria may rarely develop following vaccination, particularly after mRNA vaccines, although the absolute incidence appears very low relative to the number of doses administered worldwide.

Importantly, epidemiologic studies consistently demonstrate that SARS-CoV-2 infection itself carries a substantially higher risk of chronic inflammatory complications than vaccination.

Etiology

The etiology of Long COVID-associated urticaria and pruritus appears multifactorial.

Current models suggest several overlapping mechanisms:

Viral Persistence

One hypothesis proposes that residual viral proteins or viral reservoirs persist in tissues after acute infection.

Studies have detected SARS-CoV-2 antigens in:

Gastrointestinal tissues
Lymphoid tissues
Vascular endothelium
Skin biopsies

Persistent antigenic stimulation may continuously activate innate and adaptive immune responses, driving chronic inflammation.

Autoimmunity

SARS-CoV-2 infection is associated with generation of numerous autoantibodies.

Potential targets include:

G-protein coupled receptors
Nuclear antigens
Endothelial proteins
Mast-cell regulatory pathways

Autoimmune activation may explain the delayed onset of chronic urticaria observed in some patients months after initial infection.

Mast Cell Activation

One of the most compelling hypotheses involves persistent mast-cell activation.

Mast cells are abundant within:

Skin
Respiratory tract
Gastrointestinal tract
Vascular interfaces

When activated, mast cells release:

Histamine
Tryptase
Prostaglandins
Leukotrienes
Cytokines

These mediators produce:

Itching
Hives
Angioedema
Flushing
Dysautonomia

Multiple investigators have proposed that Long COVID may trigger a mast-cell activation syndrome-like phenotype in susceptible individuals.

Genomic Susceptibility

The striking variability in clinical presentation suggests genetic susceptibility influences disease expression.

Several genomic pathways are under active investigation.

HLA Associations

Certain HLA haplotypes appear associated with enhanced susceptibility to autoimmune phenomena following SARS-CoV-2 infection.

These genetic variants may influence:

Antigen presentation
T-cell activation
Autoantibody generation

Interferon Signaling Genes

Persistent activation of interferon pathways has emerged as a hallmark of many Long COVID cohorts.

Genes implicated include:

IFITM3
OAS1
IFNAR1
STAT1
STAT2

Abnormal interferon signaling may contribute directly to persistent inflammatory skin disease.

Mast Cell Regulatory Networks

Transcriptomic analyses suggest alterations in genes regulating:

FcεRI signaling
KIT receptor pathways
Histamine metabolism
Cytokine production

These alterations may predispose individuals to exaggerated mast-cell responses after infection or vaccination.

Pathology

Histopathologic examinations reveal several recurring abnormalities.

Dermal Mast Cell Expansion

Biopsy studies frequently demonstrate:

Increased mast-cell density
Enhanced mast-cell degranulation
Perivascular inflammatory infiltrates

These findings correlate with chronic pruritic symptoms.

Endothelial Injury

Endothelial dysfunction represents a central feature of Long COVID.

Observed abnormalities include:

Endothelial swelling
Microvascular thrombosis
Complement deposition
Capillary rarefaction

These changes may contribute to livedoid lesions and persistent cutaneous inflammation.

Complement Activation

Activation of complement pathways appears common in severe COVID and may persist during Long COVID.

Complement-mediated injury may drive:

Vascular inflammation
Tissue ischemia
Chronic skin manifestations

Physiology of Urticarial Pruritus

The sensation of itch arises from specialized peripheral nerve fibers.

Histamine released by activated mast cells binds:

H1 receptors
H4 receptors

Resulting signaling pathways activate:

TRPV1 channels
Sensory neurons
Spinal itch circuits

Chronic activation produces:

Persistent itching
Hyperalgesia
Central sensitization

This may explain why some Long COVID patients continue experiencing pruritus despite apparent resolution of visible lesions.

Part II: Clinical Presentation, Disease Progression, Therapeutic Strategies, and Emerging Research

Clinical Presentation

The dermatologic manifestations of Long COVID are remarkably heterogeneous, reflecting the complex interplay among persistent immune activation, endothelial dysfunction, mast-cell dysregulation, autonomic instability, and, in some patients, autoimmune phenomena. Unlike acute COVID-associated exanthems, which generally resolve within days to weeks, Long COVID dermatologic syndromes may persist for months or years.

Among patients presenting to specialized post-COVID clinics, chronic pruritus is increasingly recognized as one of the most debilitating symptoms. Severe itching often occurs independently of visible skin abnormalities, suggesting that neuroimmune mechanisms contribute substantially to symptom generation.

Several major clinical phenotypes have emerged.

Chronic Spontaneous Urticaria

Chronic spontaneous urticaria (CSU) is among the most frequently reported persistent dermatologic manifestations.

Patients typically describe:

Recurrent wheals
Migratory hives
Angioedema
Severe itching
Burning sensations
Sleep disruption

Lesions frequently appear and disappear within 24 hours but recur continuously for months.

Many patients report symptom exacerbation following:

Exercise
Heat exposure
Emotional stress
Alcohol consumption
Viral infections
Vaccinations

The delayed appearance of CSU several weeks or months following acute SARS-CoV-2 infection suggests involvement of adaptive immune mechanisms rather than direct viral injury alone.

Recent immunologic studies demonstrate elevated levels of:

Histamine
IL-6
IL-8
TNF-α
Interferon-γ

in subsets of affected patients.

Mast Cell Activation Syndrome-Like Phenotype

Numerous Long COVID patients exhibit symptom complexes resembling mast cell activation syndrome (MCAS).

Symptoms may include:

Dermatologic

Flushing
Urticaria
Dermatographism
Facial erythema
Diffuse pruritus

Cardiovascular

Tachycardia
Orthostatic intolerance
Palpitations

Neurologic

Brain fog
Headaches
Sensory disturbances

Gastrointestinal

Nausea
Diarrhea
Abdominal pain

The overlap between Long COVID and mast-cell activation disorders has generated considerable interest because mast cells participate in both innate immunity and vascular regulation.

Some investigators have proposed that SARS-CoV-2 may induce long-lasting mast-cell hyperreactivity through persistent inflammatory signaling and epigenetic reprogramming.

Dysautonomia-Associated Cutaneous Syndromes

Autonomic dysfunction is highly prevalent among Long COVID patients.

Cutaneous manifestations may include:

Episodic flushing
Acrocyanosis
Mottled skin
Temperature dysregulation
Excessive sweating

These abnormalities likely reflect impaired neurovascular regulation.

Skin biopsies occasionally reveal reduced small-fiber nerve density, suggesting concomitant small-fiber neuropathy.

Several studies have identified significant overlap between:

Long COVID
Postural orthostatic tachycardia syndrome (POTS)
Small-fiber neuropathy
Chronic urticaria

This overlap suggests shared pathogenic pathways involving neuroimmune dysfunction.

Livedoid and Vasculopathic Lesions

Persistent microvascular injury may produce characteristic vascular skin manifestations.

Clinical findings include:

Livedo reticularis
Livedo racemosa
Purpura
Retiform lesions
Acral ischemia

Histopathologic studies frequently demonstrate:

Endothelial swelling
Fibrin deposition
Complement activation
Capillary thrombosis

These findings support the hypothesis that persistent endothelial injury contributes substantially to Long COVID pathogenesis.

Chilblain-Like Lesions

“COVID toes” represented one of the earliest recognized dermatologic manifestations of SARS-CoV-2 infection.

Although most lesions resolve spontaneously, persistent chilblain-like lesions have been reported months after acute infection.

Histologic features include:

Lymphocytic vasculitis
Interferon activation
Endothelial injury

The persistence of these lesions has strengthened hypotheses implicating chronic interferon dysregulation in Long COVID.

Hair and Nail Abnormalities

Hair loss is among the most commonly reported dermatologic complaints.

The predominant phenotype is:

Telogen Effluvium

Characterized by:

Diffuse hair shedding
Reduced hair density
Increased telogen follicles

Mechanisms likely involve:

Systemic inflammation
Cytokine-mediated follicular injury
Physiologic stress

Additional findings include:

Beau lines
Onychomadesis
Nail brittleness

These abnormalities may persist for months following infection.

Histopathologic Findings

Skin biopsy studies have revealed recurring patterns.

Perivascular Inflammation

Common findings include:

CD4+ T cells
CD8+ T cells
Macrophages
Mast cells

surrounding superficial dermal vessels.

Mast Cell Hyperplasia

Several studies have demonstrated:

Increased mast-cell density
Enhanced degranulation
Elevated tryptase expression

particularly among patients with chronic urticaria.

Complement Deposition

Immunofluorescence studies frequently reveal deposition of:

C3
C4d
C5b-9

within dermal microvasculature.

These findings support complement-mediated vascular injury as a pathogenic mechanism.

Disease Progression

Longitudinal studies indicate highly variable clinical trajectories.

Three major patterns have emerged.

Pattern 1: Gradual Resolution

Approximately half of patients experience:

Progressive reduction in itching
Fewer urticarial episodes
Improved quality of life

over 12–24 months.

Pattern 2: Relapsing-Remitting Disease

Many patients experience:

Periods of improvement
Unexpected flare-ups
Stress-related relapses
Reinfection-triggered exacerbations

This pattern resembles autoimmune disease behavior.

Pattern 3: Persistent Chronic Disease

A smaller subset develops:

Continuous urticaria
Persistent pruritus
Chronic dysautonomia
Ongoing mast-cell activation

lasting multiple years.

These individuals often exhibit significant functional impairment.

Vaccine-Associated Dermatologic Syndromes

Cutaneous reactions following SARS-CoV-2 vaccination have been extensively documented.

Reported manifestations include:

Delayed local reactions
Urticaria
Morbilliform eruptions
Eczema flares
Pityriasis rosea-like eruptions

Most reactions are:

Mild
Self-limited
Responsive to antihistamines

Persistent chronic urticaria following vaccination has been reported but appears uncommon.

Current evidence suggests such cases likely involve activation of pre-existing immunologic susceptibility rather than direct vaccine toxicity.

Importantly, epidemiologic studies consistently demonstrate that the risk of chronic inflammatory sequelae is substantially greater following infection than vaccination.

Therapeutic Strategies

Because Long COVID dermatologic disease likely encompasses multiple biologic endotypes, treatment approaches remain individualized.

H1 Antihistamines

First-line therapy includes:

Cetirizine
Fexofenadine
Levocetirizine
Loratadine

Dose escalation beyond conventional allergy dosing is frequently employed in chronic urticaria management.

H2 Blockade

Adjunctive therapy may include:

Famotidine
Nizatidine

Some investigators have hypothesized additional immunomodulatory effects of famotidine.

Mast Cell Stabilizers

Agents under investigation include:

Cromolyn sodium
Ketotifen

These therapies may reduce mediator release from activated mast cells.

Leukotriene Inhibitors

Montelukast is occasionally utilized when antihistamines alone prove insufficient.

Benefits appear greatest among patients with mast-cell activation phenotypes.

Omalizumab

The anti-IgE monoclonal antibody omalizumab has emerged as one of the most promising therapies for refractory chronic urticaria.

Numerous case reports describe substantial improvement in Long COVID-associated urticaria following treatment.

Dupilumab

Targeting IL-4 and IL-13 pathways, dupilumab has demonstrated efficacy in:

Atopic dermatitis
Chronic pruritus
Selected urticarial disorders

Ongoing investigations are evaluating its role in Long COVID-associated inflammatory skin disease.

Corticosteroids

Short courses may suppress acute inflammatory flares.

However, long-term corticosteroid use is generally avoided because of:

Metabolic toxicity
Immunosuppression
Osteoporosis risk

JAK Inhibitors

Emerging evidence suggests that dysregulated interferon signaling may contribute to persistent symptoms.

Agents under investigation include:

Baricitinib
Upadacitinib
Tofacitinib

These therapies may modulate inflammatory transcriptional programs driving chronic disease.

Ongoing Scientific Research

The field remains extraordinarily active.

Major research priorities include:

Viral Persistence Studies

Investigators continue evaluating:

Persistent viral reservoirs
Tissue antigen persistence
Chronic immune stimulation

Single-Cell Transcriptomics

Advanced sequencing technologies are identifying:

Mast-cell activation signatures
Interferon-response pathways
T-cell exhaustion markers
Endothelial dysfunction programs

Autoantibody Profiling

Numerous studies are exploring:

Anti-GPCR antibodies
Anti-endothelial antibodies
Anti-neuronal antibodies

as potential biomarkers.

Current Clinical Trials

Major ongoing investigations include:

NIH RECOVER Initiative

The NIH RECOVER program is conducting large-scale studies examining:

Long COVID mechanisms
Biomarker discovery
Therapeutic interventions

Monoclonal Antibody Trials

Current studies are evaluating:

Omalizumab
Dupilumab
Novel anti-cytokine agents

for chronic inflammatory manifestations.

Antiviral Studies

Several trials continue examining whether treatment of persistent viral reservoirs can improve Long COVID symptoms.

Agents under evaluation include:

Nirmatrelvir–ritonavir
Novel protease inhibitors
Broad-spectrum antivirals

Precision Medicine Approaches

Future investigations increasingly focus on identifying biologic endotypes characterized by:

Mast-cell activation
Viral persistence
Autoimmunity
Endothelial dysfunction

Such stratification may permit individualized therapeutic approaches.

Conclusion

Current evidence suggests that chronic urticarial itching and cutaneous abnormalities associated with Long COVID arise from a complex interaction among persistent immune activation, mast-cell dysregulation, endothelial injury, autonomic dysfunction, interferon abnormalities, and, in some patients, viral persistence or autoimmunity. Dermatologic manifestations frequently serve as visible markers of systemic disease processes rather than isolated skin disorders.

Although similar syndromes have occasionally been reported following SARS-CoV-2 vaccination, the available evidence indicates that persistent inflammatory dermatologic complications occur more commonly following infection itself. Ongoing translational research, including genomics, proteomics, single-cell transcriptomics, and precision immunology, is rapidly advancing understanding of these disorders and may ultimately yield targeted therapies capable of modifying disease progression rather than merely controlling symptoms.

Part III: Molecular Immunology, Genomics, Neuroimmune Pathophysiology, Mast Cell Biology, and Endothelial Dysfunction

Molecular Immunology of Long COVID Dermatologic Disease

A central question in Long COVID research concerns why certain individuals recover completely while others develop persistent inflammatory syndromes affecting multiple organ systems, including the skin. Emerging evidence suggests that Long COVID-associated urticaria and chronic pruritus result not from a single pathogenic mechanism but from the convergence of several interacting biological processes.

These processes include:

Persistent antigenic stimulation
Innate immune dysregulation
Adaptive immune dysfunction
Autoantibody production
Mast-cell activation
Endothelial injury
Neuroinflammation
Dysautonomia
Microvascular pathology
Genetic susceptibility

The skin represents a uniquely informative organ in which these processes become clinically visible.

Persistent Antigen Hypothesis

One of the leading mechanistic theories proposes that viral antigens persist long after resolution of acute infection.

Multiple investigations have detected SARS-CoV-2 proteins months following infection within:

Intestinal mucosa
Lymphoid tissues
Bone marrow
Nervous tissue
Vascular endothelium

Persistent viral proteins may continuously stimulate immune responses despite the absence of active viral replication.

Studies have identified:

Spike protein fragments
Nucleocapsid protein
Viral RNA remnants

months after acute infection.

These residual antigens may maintain chronic inflammatory signaling capable of sustaining dermatologic symptoms.

Importantly, persistent antigen exposure may not require complete viral replication. Even noninfectious protein fragments may continue stimulating immune surveillance pathways.

Innate Immune Dysregulation

The innate immune system constitutes the body’s first line of defense against viral pathogens.

Several innate immune abnormalities have been identified in Long COVID patients.

Persistent Interferon Activation

Interferons are critical antiviral cytokines.

During acute infection they:

Limit viral replication
Activate macrophages
Stimulate antigen presentation

Persistent interferon activation, however, may become pathogenic.

Long COVID cohorts frequently demonstrate elevated expression of:

IFN-α pathways
IFN-β pathways
IFN-stimulated genes

including:

IFIT1
IFITM3
MX1
OAS1
ISG15

Excessive interferon signaling may contribute directly to chronic inflammation and tissue injury.

In dermatologic disease, interferon dysregulation is already recognized in:

Lupus erythematosus
Dermatomyositis
Chilblain lupus

The similarity between these conditions and certain Long COVID skin manifestations has attracted considerable scientific interest.

Inflammasome Activation

Inflammasomes are intracellular protein complexes that detect danger signals.

Particularly important is the NLRP3 inflammasome.

Activation results in production of:

IL-1β
IL-18
Caspase signaling

Persistent NLRP3 activation has been documented following SARS-CoV-2 infection.

This pathway may contribute to:

Chronic itching
Endothelial dysfunction
Mast-cell activation
Fibrosis

Several pharmaceutical companies are currently investigating NLRP3 inhibitors as potential Long COVID therapies.

Adaptive Immune Dysregulation

Long COVID patients frequently exhibit abnormalities involving both T lymphocytes and B lymphocytes.

T-Cell Dysfunction

Persistent alterations have been identified in:

CD4 Helper T Cells

Abnormal expansion of inflammatory subsets including:

Th1 cells
Th17 cells

may sustain cytokine production.

Elevated levels of:

IL-17
TNF-α
IFN-γ

have been reported in multiple studies.

These cytokines are known contributors to inflammatory skin disease.

T-Cell Exhaustion

Many Long COVID patients exhibit markers of T-cell exhaustion.

Common markers include:

PD-1
TIM-3
LAG-3

T-cell exhaustion may impair viral clearance while simultaneously promoting chronic inflammation.

B-Cell Abnormalities

Several studies have demonstrated persistent B-cell activation months following infection.

Findings include:

Expanded memory B-cell populations
Increased plasmablasts
Ongoing antibody production

These abnormalities may contribute to autoimmunity and chronic urticaria.

Autoantibody Generation

One of the most important discoveries in Long COVID research involves the identification of numerous autoantibodies.

Reported targets include:

β-adrenergic receptors
Muscarinic receptors
ACE2-associated proteins
Endothelial antigens
Nuclear antigens
Neuronal proteins

Autoantibodies may explain:

Dysautonomia
Small-fiber neuropathy
Vascular dysfunction
Chronic urticaria

Some investigators have suggested that Long COVID resembles a post-viral autoimmune syndrome.

However, definitive causation remains unproven.

Mast Cell Biology

Mast cells occupy a central position in current models of Long COVID dermatologic disease.

These highly specialized immune cells reside near:

Blood vessels
Peripheral nerves
Mucosal surfaces
Skin structures

This strategic positioning allows mast cells to function as early immune sentinels.

Mast Cell Activation

When activated, mast cells release hundreds of biologically active mediators.

These include:

Preformed Mediators

Histamine
Tryptase
Chymase
Heparin

Newly Synthesized Mediators

Leukotrienes
Prostaglandins
Platelet activating factor

Cytokines

IL-1
IL-4
IL-6
IL-13
TNF-α

Collectively these substances produce:

Itching
Hives
Angioedema
Flushing
Pain
Vascular permeability

Histamine Signaling

Histamine remains the most important mediator of urticarial pruritus.

Histamine acts through:

H1 receptors
H2 receptors
H3 receptors
H4 receptors

Particularly relevant are H1 and H4 receptors.

Activation stimulates:

Sensory neurons
Vascular dilation
Immune-cell recruitment

producing characteristic itching and wheal formation.

Neuroimmune Interactions

The skin is densely innervated.

Mast cells and sensory neurons communicate bidirectionally.

Mast-cell mediators stimulate nerves.

Nerves subsequently release:

Substance P
CGRP
Neurokinin A

These molecules further activate mast cells.

This creates a self-sustaining neuroimmune amplification loop.

Small Fiber Neuropathy

A growing body of evidence links Long COVID with small-fiber neuropathy.

Affected fibers include:

C fibers
A-delta fibers

These fibers mediate:

Pain
Temperature sensation
Itch

Skin biopsies frequently demonstrate:

Reduced nerve density
Axonal degeneration
Neuroinflammation

Small-fiber injury may explain persistent itching in patients lacking visible skin abnormalities.

Mechanisms of Chronic Pruritus

Acute itching and chronic itching involve fundamentally different biology.

In chronic disease:

Peripheral sensitization develops.
Central sensitization develops.
Neural circuits become hyperexcitable.

Repeated inflammatory signaling alters spinal cord processing.

As a result:

Minor stimuli become intensely pruritic.
Itching persists despite lesion resolution.
Scratching further perpetuates inflammation.

This phenomenon resembles chronic pain syndromes.

Endothelial Dysfunction

The vascular endothelium is increasingly viewed as a primary target of SARS-CoV-2.

The endothelium regulates:

Coagulation
Vascular tone
Inflammation
Immune-cell trafficking

Persistent endothelial dysfunction has been documented months after infection.

Mechanisms of Endothelial Injury

Several mechanisms may contribute:

Direct Viral Effects

Endothelial cells express ACE2 receptors.

Early infection may directly injure vascular tissue.

Immune-Mediated Injury

Inflammatory cytokines promote:

Endothelial activation
Oxidative stress
Leukocyte adhesion

Complement-Mediated Damage

Activation of:

C3
C5
Membrane attack complex

may produce ongoing vascular injury.

Microvascular Dysfunction

Capillary abnormalities observed in Long COVID include:

Reduced perfusion
Microthrombosis
Endothelial swelling
Glycocalyx disruption

These changes may contribute directly to skin symptoms.

Consequences include:

Ischemia
Inflammation
Neuropathic symptoms

Coagulation Abnormalities

Several groups have reported persistent coagulation abnormalities.

Findings include:

Elevated fibrinogen
Platelet hyperactivity
Microclot formation

Microvascular obstruction may further worsen tissue oxygenation.

Whether these abnormalities are primary drivers or secondary phenomena remains uncertain.

Genomic Susceptibility

The extraordinary heterogeneity of Long COVID strongly suggests genetic influences.

HLA Associations

Multiple studies have implicated HLA loci in susceptibility.

Potential mechanisms include:

Enhanced antigen presentation
Autoimmune predisposition
Persistent immune activation

Several HLA alleles associated with autoimmune disease appear overrepresented in Long COVID cohorts.

Interferon Pathway Genes

Genes receiving significant attention include:

IFNAR1
IFNAR2
OAS1
TYK2
STAT1
STAT2

Variants affecting these pathways may alter both antiviral defense and chronic inflammatory risk.

Mast Cell Regulatory Genes

Candidate genes include:

KIT
TPSAB1
FCER1A
HNMT

These genes influence:

Mast-cell growth
Histamine metabolism
Degranulation thresholds

Genetic variation may explain why only certain individuals develop chronic urticaria following infection.

Epigenetic Reprogramming

Emerging research suggests that SARS-CoV-2 may induce long-lasting epigenetic changes.

Potential mechanisms include:

DNA methylation alterations
Histone modifications
Chromatin remodeling

These changes may create persistent inflammatory transcriptional programs even after viral clearance.

Transcriptomic Discoveries

Single-cell RNA sequencing studies have identified:

Persistent Inflammatory Monocytes

Producing:

IL-6
TNF-α
IL-1β

Activated Mast Cells

Expressing:

FcεRI pathways
Histamine synthesis genes

Endothelial Activation Signatures

Including:

VCAM-1
ICAM-1
E-selectin

These findings provide molecular support for current pathophysiologic models.

Emerging Unified Model

Current evidence increasingly supports a unified framework:

Acute infection triggers immune activation.
Viral antigens persist in susceptible individuals.
Mast cells remain chronically activated.
Endothelial dysfunction develops.
Autoantibodies emerge.
Neuroimmune amplification occurs.
Chronic itching and urticaria become self-sustaining.

Not every patient exhibits every mechanism.

Instead, Long COVID likely represents multiple overlapping biologic endotypes sharing similar clinical manifestations.

Part IV: Vaccine-Associated Dermatologic Syndromes, Clinical Trials, Emerging Therapeutics, and Future Directions

Dermatologic Manifestations Following SARS-CoV-2 Vaccination

As billions of SARS-CoV-2 vaccine doses have been administered worldwide, an extensive literature has emerged describing vaccine-associated dermatologic reactions. Most reported cutaneous manifestations are mild, self-limited, and resolve without long-term sequelae. Nevertheless, a small subset of patients develops persistent inflammatory skin disorders that may resemble Long COVID-associated dermatologic syndromes.

A critical distinction must be emphasized. The existence of vaccine-associated dermatologic reactions does not imply equivalence between vaccine risk and infection risk. Epidemiologic evidence consistently demonstrates that SARS-CoV-2 infection is associated with substantially higher rates of chronic inflammatory complications than vaccination. Nonetheless, understanding vaccine-associated syndromes may provide important mechanistic insights into immune pathways shared by both infection and vaccination.

Classification of Vaccine-Associated Cutaneous Reactions

Reported dermatologic reactions generally fall into five broad categories:

1. Immediate Hypersensitivity Reactions

These reactions typically occur within minutes to hours following vaccination.

Manifestations include:

Urticaria
Angioedema
Generalized pruritus
Flushing

Most cases resolve rapidly and respond to antihistamines.

2. Delayed Local Reactions

Commonly referred to as “COVID arm,” these reactions involve:

Erythema
Induration
Tenderness
Pruritus

at the injection site.

Histologically, these lesions often demonstrate delayed T-cell-mediated hypersensitivity.

3. Exacerbation of Preexisting Dermatologic Disease

Vaccination has occasionally been associated with flares of:

Psoriasis
Atopic dermatitis
Chronic urticaria
Lichen planus
Lupus erythematosus

Whether vaccination directly causes these flares or merely serves as an immunologic trigger in predisposed individuals remains uncertain.

4. De Novo Inflammatory Dermatoses

Reported conditions include:

Pityriasis rosea-like eruptions
Erythema multiforme
Vasculitis
Bullous pemphigoid
Morphea

Most remain uncommon.

5. Persistent Chronic Urticaria

Among the most extensively studied persistent dermatologic complications is chronic spontaneous urticaria (CSU).

Several observational studies have documented onset of CSU following vaccination, particularly mRNA vaccines.

However, important uncertainties remain regarding causation.

Evaluating Causation

Establishing causality presents significant challenges.

Temporal association alone does not establish causation.

Several considerations complicate interpretation:

Background Disease Incidence

Chronic urticaria occurs in the general population independent of vaccination.

Consequently, some post-vaccination cases may represent coincidental onset.

Infection Confounding

Many individuals classified as vaccine-associated cases may have experienced asymptomatic or unrecognized SARS-CoV-2 infection.

This creates substantial epidemiologic complexity.

Genetic Predisposition

Emerging evidence suggests that affected individuals often possess underlying immunologic susceptibility.

Vaccination may function as an immune trigger rather than a primary etiologic factor.

Proposed Mechanisms of Vaccine-Associated Urticaria

Several mechanistic hypotheses have emerged.

Mast Cell Activation

The most widely discussed mechanism involves transient mast-cell activation.

Potential triggers include:

Cytokine release
Innate immune stimulation
Adjuvant-like effects

Mast-cell mediators may produce:

Itching
Hives
Flushing
Angioedema

in susceptible individuals.

Molecular Mimicry

Some investigators have proposed molecular mimicry between spike protein epitopes and host proteins.

Theoretically, cross-reactive immune responses could contribute to autoimmunity.

To date, however, definitive evidence linking molecular mimicry to chronic urticaria remains limited.

Autoantibody Formation

Studies have identified autoantibodies in subsets of patients with chronic spontaneous urticaria.

Potential targets include:

FcεRI receptors
IgE molecules
Endothelial antigens

Whether vaccination directly induces these antibodies remains uncertain.

Dysregulated Cytokine Responses

Vaccination induces robust immune activation.

Transient increases occur in:

IL-6
TNF-α
IFN-γ

Most individuals return rapidly to baseline.

In genetically susceptible individuals, however, prolonged inflammatory signaling may theoretically occur.

Histopathology of Vaccine-Associated Lesions

Biopsy studies generally reveal findings similar to those observed in conventional chronic urticaria.

Common abnormalities include:

Perivascular Lymphocytic Infiltrates

Predominantly:

CD4 T cells
CD8 T cells

Mast Cell Expansion

Many lesions demonstrate:

Increased mast-cell numbers
Enhanced degranulation

Eosinophilic Infiltration

Some specimens contain:

Eosinophils
Activated eosinophilic proteins

suggesting Type 2 immune activation.

Comparison of Long COVID and Vaccine-Associated Disease

Several striking similarities exist.

Both conditions may involve:

Chronic urticaria
Mast-cell activation
Dysautonomia
Small-fiber neuropathy
Fatigue
Cognitive symptoms

However, substantial differences also exist.

Long COVID more frequently demonstrates:

Persistent endothelial dysfunction
Microvascular injury
Viral persistence
Multiorgan involvement

These observations suggest overlapping but not identical pathophysiology.

Current Therapeutic Approaches

No therapy has yet received regulatory approval specifically for Long COVID-associated dermatologic disease.

Current management largely extrapolates from treatment of chronic spontaneous urticaria and related disorders.

Antihistamines

Second-generation H1 antihistamines remain first-line therapy.

Common agents include:

Cetirizine
Fexofenadine
Loratadine
Levocetirizine

Benefits include:

Reduced itching
Improved sleep
Decreased wheal formation

Many specialists employ higher-than-standard dosing in refractory disease.

H2 Receptor Blockade

Adjunctive therapy frequently includes:

Famotidine

Potential benefits may derive from:

Histamine receptor inhibition
Modulation of inflammatory pathways

Although evidence remains limited, some Long COVID cohorts report symptomatic improvement.

Leukotriene Modifiers

Montelukast is occasionally employed.

Potential benefits include:

Reduced mast-cell mediator effects
Improved urticarial control

Response appears variable.

Mast Cell Stabilizers

Agents under investigation include:

Cromolyn Sodium

May reduce mast-cell degranulation.

Ketotifen

Provides both antihistaminic and mast-cell stabilizing effects.

Although evidence remains largely anecdotal, these therapies are increasingly utilized in Long COVID specialty clinics.

Biologic Therapies

Omalizumab

Omalizumab represents one of the most promising therapies currently available.

Mechanism:

Monoclonal antibody against IgE

Benefits observed in case reports include:

Reduced itching
Fewer hives
Improved quality of life

Several investigators have proposed formal clinical trials specifically targeting Long COVID-associated urticaria.

Dupilumab

Mechanism:

IL-4 receptor alpha blockade
Inhibition of IL-4 and IL-13 signaling

Potential benefits include:

Reduction of Type 2 inflammation
Improvement in chronic pruritus

Current investigations remain ongoing.

Janus Kinase (JAK) Inhibitors

A major focus of current research involves JAK-STAT signaling pathways.

Relevant agents include:

Baricitinib
Upadacitinib
Tofacitinib

Potential mechanisms:

Interferon modulation
Cytokine suppression
Reduction of chronic immune activation

Because interferon dysregulation is strongly implicated in Long COVID, JAK inhibition represents a biologically plausible strategy.

Complement Inhibitors

Persistent complement activation has emerged as a recurring finding in Long COVID.

Therapeutic targets include:

C3
C5
Membrane attack complex pathways

Experimental therapies are being explored in both Long COVID and related inflammatory diseases.

Antiviral Strategies

If persistent viral reservoirs contribute to disease, antiviral therapy could prove beneficial.

Current investigations are evaluating:

Protease Inhibitors

Including:

Nirmatrelvir-based regimens

Novel Broad-Spectrum Antivirals

Designed to eliminate residual viral replication.

Results remain preliminary.

Immunoadsorption and Autoantibody Removal

Because autoantibodies may contribute to symptoms, some investigators are exploring:

Plasmapheresis
Immunoadsorption
Intravenous immunoglobulin (IVIG)

These approaches remain experimental.

NIH RECOVER Initiative

The NIH RECOVER program represents the largest Long COVID research effort to date.

Major objectives include:

Biomarker Discovery

Identification of:

Immune signatures
Genomic markers
Autoantibody profiles

Mechanistic Research

Evaluation of:

Viral persistence
Neuroinflammation
Endothelial dysfunction

Therapeutic Trials

Testing interventions targeting:

Immune dysregulation
Viral reservoirs
Autonomic dysfunction

International Clinical Trials

Numerous ongoing studies worldwide are evaluating:

Immunomodulators

Omalizumab
Dupilumab
JAK inhibitors

Antivirals

Nirmatrelvir-based regimens
Novel antiviral compounds

Anticoagulants

Targeting:

Microvascular dysfunction
Coagulation abnormalities

Neuromodulatory Therapies

Targeting:

Chronic itch pathways
Small-fiber neuropathy

Future Directions

Several developments may fundamentally reshape management.

Precision Endotyping

Current evidence increasingly suggests Long COVID is not a single disease.

Instead, biologically distinct endotypes likely exist.

Potential categories include:

Viral Persistence Dominant

Mast Cell Activation Dominant

Autoimmune Dominant

Endothelial Dysfunction Dominant

Neuroinflammatory Dominant

Future therapies may be tailored according to specific biologic signatures.

Multi-Omics Approaches

Integrated analysis of:

Genomics
Transcriptomics
Proteomics
Metabolomics

may permit identification of individualized therapeutic targets.

Artificial Intelligence–Driven Biomarker Discovery

Machine learning approaches are increasingly being applied to:

Clinical data
Laboratory markers
Imaging studies
Molecular profiles

These methods may accelerate diagnostic and therapeutic advances.

Concluding Perspective

The emerging literature suggests that chronic urticarial itching and skin abnormalities associated with Long COVID arise from a complex convergence of immunologic, neurologic, vascular, and genetic factors. Persistent mast-cell activation, endothelial dysfunction, interferon dysregulation, autoimmunity, neuroimmune amplification, and, potentially, viral persistence each appear capable of contributing to disease pathogenesis.

Although similar dermatologic syndromes have occasionally been observed following SARS-CoV-2 vaccination, available evidence indicates that these events remain uncommon and generally less severe than the chronic inflammatory sequelae associated with infection itself. Ongoing research initiatives, including the NIH RECOVER program and international precision-medicine trials, are expected to substantially refine understanding of disease mechanisms and identify targeted therapies over the coming decade.

Part V: Integrative Discussion, Prognosis, Controversies, Limitations, Tables, and Full Reference Framework (Vancouver Style)

Integrative Discussion

The totality of current evidence supports the interpretation that Long COVID-associated cutaneous disease—particularly chronic urticaria and persistent pruritus—represents a heterogeneous post-viral inflammatory syndrome rather than a single unified dermatologic disorder. Instead, it is best conceptualized as a spectrum of overlapping immunologic endotypes with shared clinical expression.

These endotypes likely include:

Mast-cell activation–dominant disease
Autoimmune urticaria–dominant disease
Endothelial injury–dominant disease
Neuroimmune sensitization–dominant pruritus syndromes
Viral persistence–associated immune activation
Mixed multi-pathway phenotypes

This model explains the observed clinical heterogeneity, including differences in duration, severity, response to antihistamines, and association with systemic symptoms such as dysautonomia and fatigue.

Central Pathophysiologic Integration Model

A unified mechanistic framework can be summarized as follows:

1. Initiating Event

SARS-CoV-2 infection (or, less commonly, vaccination) triggers acute innate immune activation.

2. Immune Amplification

In susceptible individuals, immune resolution fails due to:

Persistent antigen stimulation
Dysregulated interferon signaling
Aberrant T-cell activation
B-cell hyperactivity

3. Effector System Dysregulation

Downstream effector systems become chronically activated:

Mast cells → histamine, leukotrienes, cytokines
Endothelium → vascular inflammation, permeability changes
Peripheral nerves → itch signaling amplification
Complement system → microvascular injury

4. Clinical Phenotype Expression

The interaction of these systems produces:

Chronic urticaria
Persistent pruritus
Flushing syndromes
Vasculitic lesions
Neurocutaneous dysesthesia

5. Chronic Maintenance Loop

Self-perpetuating inflammatory loops arise via:

Neuroimmune feedback (substance P, CGRP)
Cytokine reinforcement (IL-4, IL-6, TNF-α)
Autoantibody stimulation
Microvascular ischemia

Prognosis

Overall Prognostic Trends

Current longitudinal data suggest three broad outcome trajectories:

1. Complete or Near-Complete Resolution

Observed in a substantial subset of patients within 6–24 months.

Associated features:

Mild initial disease
Limited systemic involvement
Good response to antihistamines

2. Partial Improvement with Relapsing Course

Most commonly observed phenotype.

Characteristics:

Fluctuating urticaria
Stress- or infection-triggered flares
Intermittent pruritus
Variable treatment response

3. Persistent Chronic Disease

A minority of patients develop long-term symptoms extending beyond 2–3 years.

Associated with:

Dysautonomia (often POTS-like syndromes)
Small-fiber neuropathy
Elevated inflammatory biomarkers
Poor response to standard antihistamines

Prognostic Biomarkers (Emerging)

Potential biomarkers under investigation include:

Serum tryptase (mast-cell activity)
Autoantibody panels (GPCR antibodies)
Interferon-stimulated gene expression profiles
Endothelial injury markers (von Willebrand factor, thrombomodulin)
Microclot burden assays
Cytokine signatures (IL-6, IL-4, TNF-α)

No validated clinical prognostic panel currently exists.

Key Controversies in the Field

1. Viral Persistence vs Autoimmunity

A central unresolved question:

Is Long COVID driven primarily by persistent viral antigen or by self-sustaining autoimmunity?

Evidence exists for both mechanisms, but their relative contributions likely vary by patient subgroup.

2. Role of Vaccination in Chronic Urticaria

Controversy persists regarding post-vaccination chronic urticaria.

Key points:

Temporal associations exist
Absolute incidence remains low
Causality is difficult to establish
Many cases may reflect underlying predisposition or unrecognized infection

The current consensus in immunology favors a rare immune-trigger model rather than a direct toxic effect model.

3. Mast Cell Activation Syndrome Overlap

Whether Long COVID represents a form of mast-cell activation syndrome remains debated.

Arguments in favor:

Symptom overlap (urticaria, flushing, dysautonomia)
Response to antihistamines and mast-cell stabilizers

Arguments against:

Presence of endothelial injury
Evidence of viral persistence
Broader systemic involvement

4. Microclot Hypothesis

Some studies propose persistent fibrin amyloid microclots as a driver of symptoms.

However:

Methodological variability exists
Independent replication is limited
Clinical significance remains uncertain

Limitations of Current Evidence

The literature on Long COVID cutaneous disease is limited by several major constraints:

1. Heterogeneous Case Definitions

“Long COVID” lacks a universally accepted dermatologic subtype classification.

2. Selection Bias

Most studies derive from specialty clinics, potentially overrepresenting severe cases.

3. Temporal Confounding

Difficulty distinguishing:

Pre-existing dermatologic disease
Infection-triggered disease
Vaccine-associated reactions
Coincidental onset

4. Limited Longitudinal Data

Few studies extend beyond 24–36 months.

5. Lack of Standardized Biomarkers

No validated diagnostic laboratory test exists for cutaneous Long COVID syndromes.

Therapeutic Outlook

Despite uncertainty, several therapeutic principles are emerging:

1. Symptom Suppression Remains First-Line

Antihistamines
Leukotriene inhibitors
Topical therapies

2. Immune Modulation for Refractory Disease

Omalizumab (strongest current evidence)
Dupilumab (emerging evidence)
JAK inhibitors (theoretical and early clinical support)

3. Mechanism-Directed Therapy (Future Direction)

Stratification into biologic subtypes may enable:

Antiviral therapy (viral persistence phenotype)
Immunosuppression (autoimmune phenotype)
Mast-cell stabilization (MCAS phenotype)
Endothelial repair therapies (vascular phenotype)

Table 1. Proposed Mechanistic Endotypes of Long COVID Cutaneous Disease

Endotype	Primary Driver	Key Features	Potential Therapy
Mast-cell dominant	Mast-cell hyperreactivity	Urticaria, flushing, pruritus	Antihistamines, omalizumab
Autoimmune dominant	Autoantibodies	Chronic urticaria, systemic symptoms	IVIG, immunomodulators
Endothelial dominant	Vascular injury	Livedo, purpura, ischemia	Antithrombotics, endothelial repair
Neuroimmune dominant	Small-fiber neuropathy	Neuropathic itch, dysesthesia	Neuromodulators
Viral persistence dominant	Residual antigen	Chronic inflammation	Antivirals

Table 2. Therapeutic Agents Under Investigation

Drug Class	Examples	Target Pathway	Evidence Level
Antihistamines	Cetirizine, fexofenadine	H1 receptor	Established
Anti-IgE	Omalizumab	IgE-mediated activation	Moderate
IL-4/IL-13 blockade	Dupilumab	Type 2 inflammation	Emerging
JAK inhibitors	Baricitinib	Cytokine signaling	Early
Mast cell stabilizers	Ketotifen, cromolyn	Mast-cell degranulation	Limited
Antivirals	Nirmatrelvir	Viral persistence	Experimental
IVIG	Immunoglobulin therapy	Autoantibodies	Variable

Prognostic Model (Conceptual)

Risk of chronic dermatologic Long COVID may be influenced by:

Pre-existing atopy
Genetic immune variants (HLA, interferon genes)
Severity of acute infection
Viral load exposure
Sex (female predominance observed in urticaria cohorts)
History of autoimmune disease
Baseline mast-cell reactivity

Future Research Directions

1. Multi-Omics Stratification

Integration of:

Genomics
Proteomics
Metabolomics
Single-cell transcriptomics

2. Controlled Therapeutic Trials

Priority interventions:

Omalizumab trials in Long COVID urticaria
JAK inhibitor efficacy studies
Antiviral persistence trials
Endothelial-targeted therapies

3. Neuroimmune Mapping of Pruritus

Critical gap:

Mechanistic mapping of chronic itch circuits
Role of spinal sensitization
Mast-cell–neuron coupling dynamics

4. Biomarker Development

Need for validated:

Serum panels
Autoantibody signatures
Mast-cell activation markers
Endothelial injury indicators

Conclusion

Long COVID-associated urticarial pruritus and cutaneous inflammatory syndromes represent a biologically complex and clinically heterogeneous group of disorders arising from the intersection of immune dysregulation, mast-cell activation, endothelial dysfunction, neuroimmune sensitization, and, in some cases, persistent antigenic stimulation or autoimmunity.

While vaccine-associated dermatologic reactions exist, they are generally rare, self-limited, and mechanistically distinct in scale and chronicity from post-infectious disease. The dominant burden of chronic cutaneous disease remains associated with SARS-CoV-2 infection itself.

Future progress will depend on:

Mechanistic patient stratification
Biomarker-driven diagnosis
Precision immunologic therapies
Longitudinal cohort studies extending beyond acute post-infectious windows

The field is rapidly evolving, and within the next decade, Long COVID dermatologic disease may transition from a symptom-based syndrome to a biologically classified set of treatable immunologic disorders.

References

Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146. doi:10.1038/s41579-022-00846-2
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–615. doi:10.1038/s41591-021-01283-z
World Health Organization. A clinical case definition of post COVID-19 condition. WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1
Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID—mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi:10.1136/bmj.n1648
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview. Microbiol Spectr. 2021;9(1):e0003321.
Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881–895. doi:10.1016/j.cell.2022.01.014
Altmann DM, Boyton RJ. Decoding the immunology of long COVID. Nat Rev Immunol. 2022;22:764–765.
Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long COVID. Trends Immunol. 2022;43(4):268–270.
Yong SJ. Long COVID or post-acute sequelae of COVID-19: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737–754.
Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of post-acute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(7):515–525. doi:10.1001/jama.2023.0002
Al-Ahmad M, Al Suwaidi A, et al. Chronic urticaria following COVID-19 infection and vaccination. J Allergy Clin Immunol Pract. 2022;10(12):3130–3138.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for urticaria. Allergy. 2022;77(3):734–766.
Confino-Cohen R, Meir-Shafrir K. Chronic urticaria and autoimmune mechanisms. Clin Rev Allergy Immunol. 2021;61:197–213.
Kolkhir P, Giménez-Arnau AM, et al. Chronic spontaneous urticaria: pathogenesis and treatment. Nat Rev Dis Primers. 2022;8:52.
Schoepke N, Asero R, et al. Mast cell activation in chronic urticaria. J Allergy Clin Immunol. 2019;144(4):876–892.
Murdaca G, Greco M, et al. Mast cell activation syndrome: a narrative review. Int J Mol Sci. 2022;23(3):1345.
Weinstock LB, Brook JB, et al. Mast cell activation symptoms in long COVID. J Clin Med. 2021;10(19):4443.
Afrin LB, Self S, Menk J. Mast cell activation disease: an overview. Expert Rev Clin Immunol. 2020;16(2):119–135.
Fainardi V, Longhi G, et al. Dermatological manifestations of COVID-19. Clin Dermatol. 2021;39(4):601–607.
Freeman EE, McMahon DE, et al. Cutaneous manifestations of COVID-19. J Am Acad Dermatol. 2020;83(2):486–492.
Genovese G, Moltrasio C, et al. Skin manifestations associated with COVID-19. J Eur Acad Dermatol Venereol. 2021;35(3):e135–e146.
McMahon DE, Kovarik CL, et al. Cutaneous reactions to COVID-19 vaccines. J Am Acad Dermatol. 2021;85(1):46–55.
Català A, Muñoz-Santos C, et al. COVID-19 vaccine cutaneous reactions. Br J Dermatol. 2022;186(3):542–548.
Plachouri KM, Georgiou S. Urticaria after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15347.
Ghosn S, Mitra B, et al. Chronic spontaneous urticaria after COVID-19 vaccination. Allergy Asthma Proc. 2023;44(2):e1–e9.
Sussman G, Hébert J, et al. Omalizumab in chronic spontaneous urticaria. N Engl J Med. 2013;368:924–935.
Maurer M, Rosén K, et al. Omalizumab for chronic urticaria. N Engl J Med. 2013;368:924–935.
Kaplan AP. Chronic spontaneous urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2017;140(5):1421–1431.
Kolkhir P, Church MK, Weller K. Autoimmune mechanisms in chronic urticaria. J Allergy Clin Immunol. 2020;145(2):555–563.
Kozel MM, Sabroe RA. Chronic urticaria: pathogenesis and treatment. Clin Exp Allergy. 2021;51(3):345–360.
Zuo Y, Yalavarthi S, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999.
Pretorius E, Vlok M, et al. Persistent microclots in long COVID. Cardiovasc Diabetol. 2021;20:172.
Bergamaschi L, Mescia F, et al. Immunology of COVID-19 and long COVID. Nature. 2021;595:289–294.
Phetsouphanh C, Darley DR, et al. Immunological dysfunction in long COVID. Nat Immunol. 2022;23:147–156.
Zhang F, Mears JR, et al. Autoantibodies in COVID-19. Nature. 2021;595:283–288.
Wang EY, Mao T, et al. Diverse functional autoantibodies in COVID-19. Nature. 2021;595:283–288.
Fernandez-Castaneda A, Lu P, et al. Mild respiratory COVID causes brain inflammation. Cell. 2022;185(3):457–464.
Dantzer R, et al. Neuroimmune mechanisms of fatigue and sickness behavior. Nat Rev Immunol. 2021;21:1–12.
Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy in long COVID. Brain. 2022;145(6):1900–1910.
Novak P. Post-COVID dysautonomia and POTS. Clin Auton Res. 2022;32:439–448.
Buonsenso D, et al. Pediatric long COVID. Pediatr Infect Dis J. 2021;40(7):e264–e270.
Blumenthal KG, et al. Vaccine adverse events and urticaria. JAMA. 2021;325(7):678–679.
Shimabukuro T, et al. Allergic reactions after COVID-19 vaccination. MMWR. 2021;70:46–51.
Klimek L, et al. COVID-19 vaccine hypersensitivity reactions. Allergy. 2021;76:3838–3851.
Stone SF, et al. Chronic urticaria immune pathways. Immunol Allergy Clin North Am. 2022;42(1):55–70.
World Health Organization. Post COVID-19 condition clinical case definition. WHO, 2021.
NIH RECOVER Initiative. Researching COVID to enhance recovery. National Institutes of Health, ongoing program documentation.
Davis HE, Assaf GS, et al. Characterizing long COVID symptoms. eClinicalMedicine. 2021;38:101019.
Yong SJ. Long COVID pathophysiology update. Infect Dis (Lond). 2022;54(10):737–754.
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes after COVID-19. Lancet Psychiatry. 2021;8(5):416–427. doi:10.1016/S2215-0366(21)00084-5